Revisions to the guidelines for atopic dermatitis treatment
By Hwang, Byung-woo
24.08.01 05:58:44
가나다라
0
New treatment options all rated grade 'A' recommendations…no restrictions on the type of medicines for replacement therapy when initial treatment fails
Emphasizes the necessity of 'biological agent-JAK inhibitor' replacement therapy for treating moderate-to-severe atopic dermatitis
As the market for atopic dermatitis rapidly shifts due to the introduction of new drugs, domestic guidelines are being revised in nine years, and therapeutic guidelines are also changing.
The guidelines now suggest a higher recommendation grade for treatments, including biological agents and JAK inhibitors, for use in patients with moderate-to-severe symptoms. They also include detailed recommendations to solve the issue of replacement therapy, which experts focus on.
▲(Clockwise from upper left) Product photos of Dupixent, Rinvoq, Olumiant, Adtralza, and Cibinqo.
The Korea Atopic Dermatitis Association (KADA) announced on July 31st the '2024 Guidelines for the Treatment of Atopic Dermatitis in Korea.' This guidelines have been revised after nine years, since 2015.
Hwang, Byung-woo(tuai@dailypharm.com)
If you want to see the full article, please JOIN US (click)